Evidence for the Involvement of Glu-355 in the Catalytic Action of Human \( \beta \)-Hexosaminidase B*

Mark Pennybacker‡‡, Christina G. Schuette‡‡‡, Bernd Liessem‡§, Stefan T. Hepbildikler¶, Jennifer A. Kopetka‡, Matthew R. Ellis‡‡, Rachel Myerowitz**, Konrad Sandhoff, and Richard L. Proia‡‡‡

* From the ‡Section on Biochemical Genetics, Genetics and Biochemistry Branch, NIDDK, National Institutes of Health, Bethesda, Maryland 20892, the §Institut für Organische Chemie und Biochemie der Universität Bonn, Gerhard-Domagk-Strasse 1, 53121 Bonn Germany, and the ¶Biology Department, St. Mary’s College of Maryland, St. Mary’s City, Maryland 20686.

In a previous study the photactivatable affinity probe, 3-azi-1-[(6-\(^3\)H)2-acetamido-2-deoxy-1-\( \beta \)-D-galactopyranosyl(thio)l]-butane, was used to identify the active site of \( \beta \)-hexosaminidase B, a \( \beta \)-subunit dimer (Liessem, B., Glombitza, G. J., Knoll, F., Lehmann, J., Kellermann, J., Lottspeich, F., and Sandhoff, K. (1995) J. Biol. Chem. 270, 23693–23699). The probe predominately labeled Glu-355, a highly conserved residue among hexosaminidases. To determine if Glu-355 has a role in catalysis, \( \beta \)-subunit mutants were prepared with the Glu-355 codon altered to either Ala, Gln, Asp, or Trp. After expression of mutants proteins using recombinant baculovirus, the enzymes were defrayed in part by the payment of page charges. This article must undergo proteolytic processing to a mature lysosomal form.

The \( \beta \)-hexosaminidases degrade glycoproteins, glycolipids, and proteoglycans through the release of terminal \( \beta \)-glycosidically linked N-acetylgalcosamine or N-acetylglactosamine residues. Each subunit possesses an active site within the context of the dimeric structure of the holoenzyme. The \( \alpha \) and \( \beta \) active sites, although functionally very similar, exhibit differences in their ability to hydrolyze sulfated substrates (5). Significant substrate specificity differences also exist between the isozymes. Most notably, only the heterodimer \( \beta \)-hexosaminidase A together with the \( G_{M2} \)\(^1 \) activator protein is able to degrade \( G_{M2} \) ganglioside at significant rates (6). The \( G_{M2} \) activator protein functions through binding the ganglioside substrate and interacting with \( \beta \)-hexosaminidase A. The release of the terminal N-acetylgalactosamine residue from the ganglioside is accomplished via the \( \alpha \)-chain active site (5, 7, 8). However, the \( \beta \)-subunit contributes essential functions in this reaction, possibly in promoting the interaction with the activator protein (9).

Mutations in the \( H E X A \) (\( \alpha \)-subunit) and \( H E X B \) (\( \beta \)-subunit) genes cause Tay-Sachs and Sandhoff diseases, respectively. Defects in the \( G M 2 A \) gene result in \( G M 2 \) activator deficiency. In each of these genetic disorders there is a massive accumulation of \( G M 2 \) ganglioside and related glycolipids in neuronal lysosomes, leading to severe neurodegeneration. In addition to \( G M 2 \) ganglioside and related glycolipids, glycosaminoglycans are also critical substrates as demonstrated by the severe mucopolysaccharidosis phenotype exhibited in mice lacking both subunits of hexosaminidase (10).

Although much progress has been made in understanding the genetics and biochemistry of the hexosaminidases, details concerning the structures of the active sites and mechanisms of catalysis have only recently emerged. The first biochemical evidence localizing an active site was presented in a study by Liessem et al. (11) using the photoaffinity reagent, \( ^3\)HATB-GalNAc. This probe was shown to label Glu-355 of the human \( \beta \)-subunit, implicating this amino acid in the architecture of the active site. To determine if Glu-355 has a role in \( \beta \)-hex-

The abbreviations used are: \( G_{M2} \) ganglioside; GalNAc\( \beta \)1-4-(NeuAcO\( \alpha \))-3-Gal(\( \beta \)1-4Glc\( \beta \)1-1Cer; \( H E X A \), the gene encoding the \( \alpha \)-subunit of \( \beta \)-hexosaminidase; \( H E X B \), the gene encoding the \( \beta \)-subunit of \( \beta \)-hexosaminidase; \( G M 2 A \), the gene encoding the \( G M 2 \) activator protein; \( M U - G l c N a c \), 4-methylumbelliferyl-2-acetamido-2-deoxy-\( \beta \)-D-glucopyranoside; \( M U - G l c N a c \), 4-methylumbelliferyl-6-sulfo-2-acetamido-2-deoxy-\( \beta \)-D-glucopyranoside; \( [\beta I A T B - G a l N a c , 3-\alpha - 1-[(6-\(^3\)H)2-acetamido-2-deoxy-1-\( \beta \)-D-galactopyranosyl(thio)l]butane; DSS, disuccinimidyl suberate; \( \delta \)-lactone, 2-acetamido-2-deoxy-\( \beta \)-D-glucosone-1,5-lactone; Tricine, \( N -(\alpha \)-hydroxy-1,1-bis(hydroxymethyl)ethyl)glycine.  

* This work was supported in part by Grant SFB 284 from the Deutsche Forschungsgemeinschaft. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

‡‡ Both authors contributed equally to this work.

‡‡‡ To whom correspondence should be addressed: Bldg. 10, Rm. 9D-20, 10 Center Dr., MSC 1810, NIH, Bethesda, MD 20892-1810. Tel.: 301-496-6774; Fax: 301-496-9878.
osaminidase B-mediated catalysis, we altered this residue by site-directed mutagenesis. The mutant β-subunits lost catalytic activity but retained their ability to bind a substrate analogue, form homo- and heterodimers, function in the context of β-hexosaminidase A in activator-dependent G₂₆₄ degradation, and undergo intracellular transport to lysosomes. These results, together with affinity labeling of Glu-355 and the recently described structure of an evolutionarily related chitinase (12), provide compelling evidence that Glu-355 has an essential role in the catalytic mechanism of human β-hexosaminidase B.

**EXPERIMENTAL PROCEDURES**

**Site-directed Mutagenesis**—The mutations were made with the Sculptor in vitro mutagenesis system from Amersham Corp. (RPN 1526) using the human β-subunit cDNA that had been cloned into M13mp18 (13). The mutant oligonucleotides (antisense) were as follows: E355A, CCCAACATTAAATCCACTGCATCTCCTCCCAATG; E355Q, CCCAACATTAAATCCACTTGATCTCCTCCCAATG; E355D, CCCAACATTAAATCCACATCTCCTCCCAATG; E355W, CCCAACATTAAATCCACTGCATCTCCTCCCAATG.

The resultant mutant cDNAs were cloned into the XbaI and SaeI sites of the pSVL vector (Pharmacia Biotech Inc.) for expression in COS-1 cells. For the production of baculoviruses, the mutant cDNAs were excised from the pSVL vector and subcloned into the XbaI/Smal sites of the baculovirus shuttle vector pVL1392 (Pharmingen). All mutant constructs were verified by DNA sequencing.

**Expression of Mutant Constructs**—Clonal recombinant baculovirus containing each of the mutant cDNAs was produced as described except that the virus producing the mutant cDNAs was identified by production of immunoreactive β-subunits rather than by enzymatic activity (9). The recombinant baculovirus contaminating wild-type β-subunit was described previously (14). Production of expression media by infection of insect cells (High Five and SF21) and co-expression of the mutant β-subunit cDNAs with the α-subunit was accomplished as described by Pennybacker et al. (9). COS-1 cells were transfected with mutant cDNAs in the pSVL vector using LipofectAMINE (Life Technologies, Inc.) according to the manufacturer’s instructions. [35S]Methionine labeling and immunoprecipitation have been described (13).

**Assay of Mutant Proteins**—Enzyme activity was determined with MU-GlcNAc and MU-GlcNAc-6-SO₄ as described previously (9). Protein concentrations were measured according to the method of Bradford (15) using bovine serum albumin as a standard. The concentration of the α-subunit, labeled in the GaINac moiety, was used to determine G₂₆₄ , degrading activity in the presence of recombinant GaINac activator (9).

**Affinity Chromatography**—The affinity gel was prepared as described by Izuimi and Suzuki (16) using 2-acetamido-2-deoxy-β-D-glucopyranosylamine as an affinity ligand. Small columns were prepared with a 1-ml bed volume and were equilibrated in 10 mM phosphate buffer (pH 6.0) containing 100 mM NaCl. Small columns were prepared with a 1-ml bed volume and were equilibrated in 10 mM phosphate buffer (pH 6.0) containing 100 mM NaCl. Small volumes of eluate were resolved by SDS-polyacrylamide gels as described by Blum et al. (18). For Western blotting, equal volumes of eluate were resolved by SDS-polyacrylamide gel electrophoresis as described above. Proteins were transferred to polyvinylidene difluoride membrane. The membranes were blocked overnight at room temperature. The membranes were washed with Tris buffer (40 mM Tris-HCl, 340 mM NaCl, 0.1% Nonidet P-40, 0.01% NaN₃, pH 7.4). After 1 h of incubation with rabbit anti-goat IgG coupled to alkaline phosphatase followed by washing in Tris buffer, the membrane was developed using 5-bromo-4-chloro-3-indolyl phosphate and 0.2 mM nitro blue tetrazolium in carbonate buffer (100 mM carbonate, 1 mM MgCl₂, 0.01% NaN₃, pH 9.8).

**Cross-linking**—Disuccinimidyl suberate (DSS, 10 mM) was freshly prepared in dimethyl sulfoxide. β-Subunit preparations (30 ng in 75 mM phosphate buffer, pH 7.5) were incubated in the presence of 0.78 mM DSS at 37°C for 30 min. Control samples contained an equivalent amount of dimethyl sulfoxide without the cross-linker. The reaction was stopped by the addition of Tris-HCl (pH 7.5) to 27 mM. The samples were electrophoresed on an SDS-polyacrylamide gel and transferred to a polyvinylidene difluoride membrane. After probing the membrane with anti-hexosaminidase B, detection was accomplished with the Vistra ECF Western blotting kit (Amersham). Probed membranes were scanned with the Storm 860 Fluorimager from Molecular Dynamics.

**RESULTS**

The codon specifying Glu-355 in the β-hexosaminidase β-subunit cDNA was altered to produce cDNAs with the following changes: E355A, E355W, E355Q, and E355D. The cDNAs were recombined into baculovirus for expression in insect cells. We previously showed that precursor enzyme can be recovered from the expression medium for analysis in a number of biochemical assays (9). The expression medium from cells infected with each recombinant virus was assayed for enzymatic activity with the synthetic substrate, MU-GlcNAc, and for β-subunit protein by Western blotting (Fig. 1). Abundant β-hexosaminidase activity was detected in medium from insect cells infected with virus expressing the unaltered β-subunit (Glu-355). In contrast, expression media containing the Glu-355 mutant β-subunits resulting from infection with baculovirus carrying any of the mutant cDNAs (E355A, E355Q, E355W, E355D) displayed very low levels of activity (<3%) relative to wild-type β-hexosaminidase B after normalization to the amount of β-subunit protein present.

The expression media were passed through miniaffinity columns containing the ligand, 2-acetamido-2-deoxy-β-D-glucopyranosylamine (Fig. 2). This is the classical affinity ligand used for purification of β-hexosaminidase via its substrate binding site (16, 19, 20). After washing the columns, elution was carried out with the high affinity competitive inhibitor, β-lactone, a transition state analogue with a submicro-molar Kᵢ. If the mutant subunits retained their substrate binding sites, they should bind to the columns and then be eluted specifically with β-lactone. The wash-through fraction obtained from each expression medium showed a complex mixture of protein species after electrophoresis on SDS-gels and visualization by silver staining. As expected, a Mr, 63,000 polypeptide, the precursor size of the β-subunit (20), was specifically eluted.
Glu-355, an Active-site Residue in β-Hexosaminidase B

The recombinant hexosaminidase B dissection of kinetic parameters with the synthetic substrate, MU-GlcNAc, was found in the medium from cells infected with wild-type virus (control). Comparable peptide was found in the medium from cells infected with catalytically impaired mutant proteins were indistinguishable enzymatic activity to be expressed (4). As seen in Fig. 3, the catalytically impaired mutant proteins were indistinguishable from catalytically active β-hexosaminidase B (Glu-355) in their capacity to be cross-linked by DSS.

Next, we tested whether the catalytically deficient mutant β-subunits could function in the context of the heterodimer β-hexosaminidase A in activator-dependent G\(_{\text{M2}}\) galangoside degradation. The α-subunit was co-expressed with each β-subunit to produce heterodimers. The resulting expression media were assayed for the capacity to degrade the galangoside (Fig. 4). The G\(_{\text{M2}}\) galangoside-degrading activities of the expression media containing the mutant heterodimers ranged from 77 to 120% of the activity of co-expressed wild-type α- and β-subunits (Fig. 4).

Finally, the mutant subunits were expressed in COS-1 cells to determine their intracellular fate (Fig. 5). After transfection, the mutant constructs did not produce enzyme activity above background levels (not shown). However, the mutant constructs did direct the production of \(M_r\) 63,000 β-subunit pre-

### Table I

| Enzyme                        | \(K_m\) \(\text{max} \) | \(V_{\text{max}}\) \(\mu\text{mol} / \text{min} / \text{mg} \) |
|-------------------------------|-------------------------|---------------------------------|
| β-Hexosaminidase A (placental)| 0.70 158               |                                 |
| β-Hexosaminidase B (placental)| 0.57 250               |                                 |
| E355                          | 0.63 174               |                                 |
| E355Q                         | 0.40 5.5               |                                 |
| E355A                         | 0.63 9.7               |                                 |
| E355W                         | 0.63 8.6               |                                 |
| E355D                         | 0.59 6.5               |                                 |
| Control                       | 0.56 8.9               |                                 |

*Determinations were carried out in duplicate; deviation did not exceed 5%. \(K_m\) and \(V_{\text{max}}\) values were calculated from double-reciprocal plots of reaction velocity versus substrate concentration.

\(V_{\text{max}}\) values were calculated from protein concentrations determined by the Bradford method. Due to the low amount of protein recovered from the affinity column, the mutant preparation \(V_{\text{max}}\) values have an experimental error of ±50%.

---

**Fig. 2. Purification of β-subunit Glu-355 (E355) mutants by substrate affinity chromatography.** Expression media prepared by infection of insect cells with baculovirus containing the unaltered β-subunit (Glu-355 (E355)), β-subunit mutants (E355Q, E355A, E355W, E355D), and the wild-type baculovirus (Control) were passed through mini-columns of 2-acetamido-N-\(\text{N}\)-aminocaproyl)-2-deoxy-\(\beta\)-gulo-pyranosylamine coupled to Sepharose. The wash-through was collected. After rinsing the column, elution was carried out with 150 mM δ-lactone. Samples of the wash-through and elution were electrophoresed on an SDS-polyacrylamide gel. The gels were then silver-stained to reveal proteins (panel A). Portions of the elution fractions were subjected to Western analysis using antibody directed at β-hexosaminidase B (panel B).

**Fig. 3. Cross-linking of β-subunit Glu-355 (E355) mutants.** Samples of baculovirus expressed β-hexosaminidase B (Glu-355 (E355)) and β-subunit mutants (E355Q, E355A, E355W, E355D) were incubated with or without DSS. The samples were electrophoresed on an SDS-polyacrylamide gel, transferred to a polyvinylidene difluoride membrane, and subjected to Western analysis using antibody directed at β-hexosaminidase B. The protein band marked by the asterisk appears after the incubation at 37 °C and likely represents a proteolytic breakdown product.
the culture media was assayed for degradation of [3H]GM2 ganglioside from an infection with wild-type baculovirus. The expressed enzyme in upon chase in a manner indistinguishable from the unaltered unimpaired. Since ganglioside degradation is mediated the presence of the b-defective protein. 

adversely affect the folding and quaternary structure of the b subunit (22). Mutations in hexosaminidase subunits impair- ing their folding and assembly leads to premature degradation in the presence of recombinant Gm6 subunit Glu-323 of human chitobiase, coincides with Glu-355 in the catalytic mechanism of hexosaminidase B. This result, the strongest biochemical evidence to date in the identification of an active site, focused our attention on this evolutionarily conserved amino acid. We have now extended these studies by analyzing mutant b-subunits with Glu-355 converted to four other amino acids, Ala, Asp, Trp, and Gln.

The mutant b-chains underwent normal proteolytic matura- tion in COS-1 cells indicative of lysosomal delivery. The capacity to pass through the endoplasmic reticulum “quality control” system is evidence for the correct folding and assembly of subunits. The structure of chitobiase indicates that the counter-ion of the hydroxyl group of the sugar substit- uent serves as a nucleophile in the reaction. Homology modeling of the catalytic domains of the human enzymes sug- gests that they adhere to the same catalytic mechanism as proposed for chitobiase (12). Significantly, sequence align- ments show that Glu-540, the proposed proton donor in chito- biase (12), coincides with Glu-323 of human biase, a member of the glycosyl hydrolase family that also includes the human Glu-355 mutations did not impair these essential functions.

FIG. 4. Activator-dependent hydrolysis of Gm6 ganglioside by heterodimers of the a-subunit and b-subunit Glu-355 (E355) mu- tants. Insect cells were co-infected with recombinant baculovirus containing a-subunit together with the unaltered b-subunit or mutant b-subunits (E355Q, E355A, E355W, E355D). The Control sample was from an infection with wild-type baculovirus. The expressed enzyme in the culture media was assayed for degradation of [3H]GM2 ganglioside in the presence of recombinant Gm6 activator protein. The activity is expressed as μmol of GM2 ganglioside cleaved/h/unit of MU-GlcNAc-6-SO4 activity. Experiments were carried out in duplicate, and deviations did not exceed 10%.

FIG. 5. Lysosomal processing of β-subunit Glu-355 (E355) mu- tants in COS-1 cells. The unaltered β-subunit (Glu-355 (E355)), mutant β-subunits (E355Q, E355A, E355W, E355D), and the empty pSVL vector were transfected into duplicate sets of COS-1 cells as indicated. After 48 h the cells were incubated with [35S]methionine for 2 h. One set of cultures was harvested (Pulse). The other was incubated further with unlabeled growth medium for 18 h before harvesting (Chase). The extracts of the radiolabeled cells were subjected to immunoprecipitation with antibody directed at β-hexosaminidase B followed by SDS-poly- acrylamide gel electrophoresis.

We found that the mutant proteins could be isolated using a substrate affinity column. This result indicates that the sub- strate binding site on the mutant proteins is sufficiently intact for interaction with the low affinity ligand, 2-acetamido-N-(α-aminocaproyl)-2-deoxy-β-D-glucopranosamine (K₀ ~0.5 mM). Mutant proteins that were affinity-isolated through their sub- strate binding site were catalytically impaired. The presence of substrate binding in association with a large decrease in enzymatic activity is, in itself, strong evidence for the involvement of Glu-355 in the catalytic mechanism of β-hexosaminidase B. Due to the high degree of sequence similarity between the α- and β-subunits and the functional similarities of their active sites, it is expected that α-subunit Glu-323, the counterpart of β-subunit Glu-355, would also be involved in catalysis medi- ated by the α-subunit. Mutagenesis of α-subunit Glu-323 also impairs catalytic activity (not shown).

Recently, the crystal structure of Serratia marcescens chito- biase, a member of the glycosyl hydrolase family that also includes the human β-hexosaminidases, was determined (12). Based on the structure of the enzyme-substrate complex, an acid-base substrate-assisted catalytic mechanism was proposed in which Glu-540 of the chitobiase functions as the catal- alytic acid while the polar acetamido group of the sugar sub- strate serves as a nucleophile in the reaction. Homology modeling of the catalytic domains of the human enzymes sug- gests that they adhere to the same catalytic mechanism as proposed for chitobiase (12). Significantly, sequence align- ments show that Glu-540, the proposed proton donor in chito- biase, coincides with Glu-323 of human α-subunit, the equiva- lent of Glu-355 in the human β-subunit. Our results, in combination with the structure of the related chitohydase, would indicate that Glu-355 serves as the proton donor during the catalytic action of β-hexosaminidase B.

Previously, two other amino acids, Arg-211 and Asp-196, were suggested to be involved in the β-hexosaminidase B catal- alytic mechanism (23, 24). However, current evidence does not support a direct role for either of these amino acids in this process. The structure of chitobiase indicates that the counter-
part of Arg-211 is involved in substrate binding and not in the catalytic mechanism (12). Asp-196 was suggested to serve as the acid catalyst in β-hexosaminidase B (24). This seems very unlikely given the very strong evidence summarized here supporting Glu-355 for this role and because all proton donors in glycosidases analyzed thus far have been found to be glutamic acid (25).

In conclusion, three independent lines of evidence provide compelling support for the involvement of Glu-355 in the catalytic mechanism mediated by β-hexosaminidase B. First, Glu-355 was uniquely labeled by an active-site affinity probe. Second, the structure of an evolutionarily related enzyme suggests the counterpart of Glu-355 functions as the catalytic acid in an acid-base enzyme mechanism. Third, the data presented in this report show that mutant β-subunits with Glu-355 altered to any of four other amino acids display minimal β-hexosaminidase B activity even though other properties of the β-subunit, including formation of the substrate binding site, subunit assembly, activator-dependent GM₂ degradation by β-hexosaminidase A, and intracellular transport, remain intact.

Acknowledgments—We thank Janet Yancey-Wrona for her comments on the manuscript. We also thank Dr. Thomas Kolter for the synthesis of radiolabeled GM₂ ganglioside and Thorsten Lemm for expression of recombinant GM₂ activator protein.

Note Added in Proof—After this manuscript was accepted for publication, Fernandes et al. (26) reported that mutagenesis of Glu-323 of the β-subunit, the equivalent of Glu-355 of the β-subunit, impairs catalytic activity, supporting our conclusions.

REFERENCES
1. Sandhoff, K., Conzelmann, E., Neufeld, E. F., Kaback, M. M., and Suzuki, K. (1989) in The Metabolic Basis of Inherited Disease (Scriver, C. R., Beaudet, A. L., Sly, W. S., and Valle, D., eds) pp. 1807–1839, McGraw-Hill Inc., New York
2. Gravel, R. A., Clarke, J. T. R., Kaback, M. M., Mahuran, D., Sandhoff, K., and Suzuki, K. (1995) in The Metabolic and Molecular Basis of Inherited Disease (Scriver, C. R., Beaudet, A. L., Sly, W. S., and Valle, D., eds) pp. 2839–2879, McGraw-Hill Inc., New York
3. Proia, R. L., and Neufeld, E. F. (1982) Proc. Natl. Acad. Sci. U. S. A. 79, 6360–6364
4. Proia, R. L., d’Azzo, A., and Neufeld, E. F. (1984) J. Biol. Chem. 259, 3350–3354
5. Kytzia, H.-J., and Sandhoff, K. (1985) J. Biol. Chem. 260, 7568–7572
6. Fürst, W., and Sandhoff, K. (1992) Biochim. Biophys. Acta 1126, 1–16
7. Conzelmann, E., and Sandhoff, K. (1979) Hoppe-Seyler’s Z. Physiol. Chem. 360, 1837–1849
8. Conzelmann, E., Burg, J., Stephan, G., and Sandhoff, K. (1982) Eur. J. Biochem. 123, 455–464
9. Pennybacker, M., Liessem, B., Moczall, H., Tifft, C. J., Sandhoff, K., and Proia, R. L. (1990) J. Biol. Chem. 271, 17377–17382
10. Sango, K., McDonald, M. P., Crawley, J. N., Mack, M. L., Tifft, C. J., Skop, E., Starr, C. M., Hoffmann, A., Sandhoff, K., Suzuki, K., and Proia, R. L. (1996) Nat. Genet. 14, 348–352
11. Liessem, B., Glombitza, G. J., Knoll, F., Lehmann, J., Kellermann, J., Lottspeich, F., and Sandhoff, K. (1995) J. Biol. Chem. 270, 32693–32699
12. Tews, I., Perrakis, A., Oppenheim, A., Duarte, Z., Wilson, K. S., and Vorgias, C. E. (1996) Nat. Struct. Biol. 3, 638–648
13. Sonderfeld-Fresco, S., and Proia, R. L. (1989) J. Biol. Chem. 264, 7692–7697
14. Boose, J. A., Tifft, C. J., Proia, R. L., and Myerowitz, R. (1990) Protein Expression Purif. 1, 111–120
15. Bradford, H. F. (1976) Anal. Biochem. 72, 248–254
16. Inumi, T., and Suzuki, K. (1983) J. Biol. Chem. 258, 6991–6999
17. Schagger, H., and von Jagow, G. (1987) Anal. Biochem. 166, 368–379
18. Blum, H., Beur, H., and Gross, H. J. (1987) Electrophoresis 8, 93–99
19. Geiger, B., and Arnon, R. (1976) Biochemistry 15, 3484–3493
20. Hasilik, A., and Neufeld, E. F. (1980) J. Biol. Chem. 255, 4937–4945
21. Licari, P. J., Jarvis, D. L., and Bailey, J. E. (1993) Biotechnol. Prog. 9, 146–152
22. Hammond, C., and Helenius, A. (1995) Curr. Opin. Cell Biol. 7, 523–529
23. Hou, Y., Tse, R., and Mahuran, D. J. (1996) Biochemistry 35, 3963–3969
24. Tse, R., Vavougios, G., Hou, Y., and Mahuran, D. J. (1996) Biochemistry 35, 7599–7607
25. Henrisaat, B., Callebaut, I., Fahrega, S., Lehn, P., Mornon, J.-P., and Davis, G. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 7090–7094
26. Fernandes, M. J. G., Yew, S., Leclerc, D., Henrisaat, B., Vorgias, C. E., Gravel, R. A., Hechtman, P., and Kaplan, F. (1997) J. Biol. Chem. 272, 814–820

Glu-355, an Active-site Residue in β-Hexosaminidase B